PD-1/PD-L1 axis; IL-2 receptor βγ (IL-2Rβγ)

Class

Tumor-activated PD-1 x IL-2 bispecific (masked/prodrug-format immunotherapy)

Pathway

Tumor-localized PD-1 checkpoint blockade combined with IL-2Rβγ agonism

This mechanism combines two immune-modulating strategies into a single molecule: blockade of the PD-1/PD-L1 checkpoint and agonism of the IL-2 receptor's beta-gamma subunits (IL-2Rβγ). PD-1 is an inhibitory receptor on T cells that, when engaged by PD-L1 on tumor or stromal cells, dampens T-cell activity and allows tumors to evade immune attack; blocking this interaction restores T-cell function. IL-2Rβγ signaling, activated by interleukin-2, drives proliferation and cytotoxic activity of T cells and natural killer cells, amplifying an immune response once T cells are no longer suppressed. Pairing checkpoint blockade with cytokine-driven expansion aims to both release the brake on immune cells and simultaneously increase their numbers and potency within a tumor. Because IL-2 signaling and checkpoint blockade can each cause significant systemic immune activation and toxicity when unrestrained, this molecule is engineered as a tumor-activated or 'masked' construct, designed to remain largely inert until it reaches the tumor microenvironment. This localization strategy is broadly relevant across solid tumor types where checkpoint inhibition alone produces limited responses, and where systemic cytokine therapy is limited by toxicity.